Trypanosoma cruzi causes Chagas disease, a neglected disease that can be divided, overall, into acute and chronic phases. Understanding the mechanisms underlying its progression is based on the parasite-host interactions occurring during the infection. Although the pathophysiology of the main symptomatic forms of Chagas disease has been the subject of several studies, little is known about their relationship with the development of different types of cancer. Therefore, knowledge regarding the molecular aspects of infection in the host, as well as the influence of the immune response in the parasite and the host, can help to understand the association between Chagas disease and tumor development. This review aims to summarize the main molecular mechanisms related to T. cruzi-dependent carcinogenic development and the mechanisms associated with tumor protection mediated by different parasite components.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biochi.2022.10.019 | DOI Listing |
Glob Epidemiol
June 2025
Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Brazil.
Unlabelled: COVID-19 is no longer a global health emergency, but it remains challenging to predict its prognosis.
Objective: To develop and validate an instrument to predict COVID-19 progression for critically ill hospitalized patients in a Brazilian population.
Methodology: Observational study with retrospective follow-up.
Arch Peru Cardiol Cir Cardiovasc
December 2024
Heart Failure and Heart Transplant Clinic, Fundación Cardiovascular de Colombia, Floridablanca, Colombia. Heart Failure and Heart Transplant Clinic Fundación Cardiovascular de Colombia Floridablanca Colombia.
Objective: Chronic Chagas Cardiomyopathy (CCC) carries a high risk of embolic events due to structural changes in the left ventricle and frequent conduction disorders. However, there is limited data on anticoagulant prescription patterns and factors influencing the use of direct oral anticoagulants (DOACs) in these patients. This study aims to characterize CCC patients based on the anticoagulant therapy received and identify factors associated with DOACs use.
View Article and Find Full Text PDFStem Cell Res Ther
January 2025
Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
Background: Despite many years of investigation into mesenchymal stem cells (MSCs) and their potential for treating inflammatory conditions such as COVID-19, clinical outcomes remain variable due to factors like donor variability, different tissue sources, and diversity within MSC populations. Variations in MSCs' secretory and proliferation profiles, and their proteomic and transcriptional characteristics significantly influence their therapeutic potency, highlighting the need for enhanced characterization methods to better predict their efficacy. This study aimed to evaluate the biological characteristics of MSCs from different tissue origins, selecting the most promising line for further validation in a K18-hACE2 mouse model of SARS-CoV-2 infection.
View Article and Find Full Text PDFAnimal
December 2024
Department of Animal Sciences, Washington State University, Pullman, WA 99164, USA; William H. Miner Agricultural Research Institute, Chazy, NY 12921, USA. Electronic address:
Available literature on the effect of various physical forms of starter feed (PFSF) on calf performance is conflicting. Thus, this study aimed to investigate the effect of the PFSF on feed intake, growth performance, blood metabolites, and the health of dairy calves. Twenty-four female Holstein calves (5-d-old; 40.
View Article and Find Full Text PDFJ Nutr Metab
January 2025
Graduate Program in Medical Sciences, Fluminense Federal University (UFF), Niterói, Rio de Janeiro, Brazil.
Tocotrienols, isomers of vitamin E, may provide an effective nutritional strategy to mitigate common cardiovascular risks such as dyslipidemia, inflammation, and oxidative stress in patients with chronic kidney disease (CKD). This double-blind, placebo-controlled, randomized clinical trial aimed to evaluate the effects of a tocotrienol-rich fraction (TRF) supplementation (300 mg/day) on oxidative stress and inflammatory markers, including transcription factors in nondialysis (ND) and hemodialysis (HD) CKD patients for three months. Interleukin-6, tumor necrosis factor- (IL-6 and TNF-), C-reactive protein (CRP), lipid peroxidation, biochemical parameters, and transcription factors such as NRF2 and NF-B mRNA expression were evaluated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!